Antibody–drug conjugate combined with chemoimmunotherapy: Redefining the neoadjuvant strategy for human epidermal growth factor receptor 2‐overexpressing locally advanced gastric cancer
Clinical and Translational Discovery · 2026-06 · 6 (3)
DOI: 10.1002/ctd2.70159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Discovery, online erschienen am 18.06.2026. Verfasst von Shulun Nie und 4 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Nie, S., Wang, C., Cao, X., Song, S., & Wang, Y. (2026). Antibody–drug conjugate combined with chemoimmunotherapy: Redefining the neoadjuvant strategy for human epidermal growth factor receptor 2‐overexpressing locally advanced gastric cancer. Clinical and Translational Discovery, 6(3). https://doi.org/10.1002/ctd2.70159
Vancouver
Nie S, Wang C, Cao X, Song S, Wang Y. Antibody–drug conjugate combined with chemoimmunotherapy: Redefining the neoadjuvant strategy for human epidermal growth factor receptor 2‐overexpressing locally advanced gastric cancer. Clinical and Translational Discovery. 2026;6(3). doi:10.1002/ctd2.70159
BibTeX
@article{Nie2026,
author = {Nie, Shulun and Wang, Cunliang and Cao, Xiaolan and Song, Shuyi and Wang, Yu},
title = {Antibody–drug conjugate combined with chemoimmunotherapy: Redefining the neoadjuvant strategy for human epidermal growth factor receptor 2‐overexpressing locally advanced gastric cancer},
journal = {Clinical and Translational Discovery},
year = {2026},
volume = {6},
number = {3},
doi = {10.1002/ctd2.70159}
}
EUVIMED